Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. (Q51821033)
Jump to navigation
Jump to search
scientific article published on 19 June 2014
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. |
scientific article published on 19 June 2014 |
Statements
Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial. (English)
1 reference
1 reference
1 reference
1 reference
1 reference
Dean Naisbitt
1 reference
William Greenhalf
1 reference
Gary Middleton
1 reference
Jonathan Wadsley
1 reference
David Propper
1 reference
Stephen Falk
1 reference
Fareeda Coxon
1 reference
Nick Wadd
1 reference
Pippa Corrie
1 reference
Charlotte Rawcliffe
1 reference
Alan Anthoney
1 reference
Martin Eatock
1 reference
Paul Silcocks
1 reference
Paul Ross
1 reference
Tom Roques
1 reference
Mark Harrison
1 reference
Tim Iveson
1 reference
Angus Robinson
1 reference
Karen McAdam
1 reference
Jeff Evans
1 reference
Caroline Archer
1 reference
Angel Garcia-Alonso
1 reference
Marianne Nicolson
1 reference
William Steward
1 reference
Gemma Nanson
1 reference
19 June 2014
1 reference
15
1 reference
8
1 reference
829-840
1 reference